Bioactive natural products in COVID-19 therapy
- PMID: 36059994
- PMCID: PMC9438897
- DOI: 10.3389/fphar.2022.926507
Bioactive natural products in COVID-19 therapy
Abstract
The devastating COVID-19 pandemic has caused more than six million deaths worldwide during the last 2 years. Effective therapeutic agents are greatly needed, yet promising magic bullets still do not exist. Numerous natural products (cordycepin, gallinamide A, plitidepsin, telocinobufagin, and tylophorine) have been widely studied and play a potential function in treating COVID-19. In this paper, we reviewed published studies (from May 2021 to April 2022) relating closely to bioactive natural products (isolated from medicinal plants, animals products, and marine organisms) in COVID-19 therapy in vitro to provide some essential guidance for anti-SARS-CoV-2 drug research and development.
Keywords: COVID-19; SARS-CoV-2; cordycepin; gallinamide A; natural products; plitidepsin; telocinobufagin; tylophorine.
Copyright © 2022 Wang, Wang, Yang and Song.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Alhadrami H. A., Burgio G., Thissera B., Orfali R., Jiffri S. E., Yaseen M., et al. (2022). Neoechinulin A as a promising SARS-CoV-2 Mpro inhibitor: In vitro and in silico study showing the ability of simulations in discerning active from inactive enzyme inhibitors. Mar. Drugs 20 (3), 163. 10.3390/md20030163 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
